Crinetics Pharmaceuticals Income Statement (2017-2026) | CRNX

1Y3Y5Y7Y10YAll
Download Data
Income Statement Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
1.08M3.13M0.44M0.46M0.71M2.68M0.99M0.35M0.64M0.40M0.36M1.03M0.14M6.16M10.73M
Cost of Revenue (Quarter)
0.20M
Gross Profit (Quarter)
0.36M10.53M
Operating items
Research & Development (Quarter)
20.49M21.58M24.60M28.25M32.99M31.99M-61.57M38.47M40.64M43.84M45.58M53.34M58.34M61.91M66.57M76.24M26.20M90.46M85.05M100.08M
Selling, General & Administrative (Quarter)
5.60M6.23M7.36M8.71M10.49M11.93M11.27M12.19M13.34M15.48M17.08M20.83M24.84M25.89M28.18M35.53M49.84M52.27M53.70M50.83M
Other Operating Expenses (Quarter)
98.56M54.10M1.08M0.20M
Operating Expenses (Quarter)
26.09M27.81M31.97M36.96M43.48M43.91M48.27M50.66M53.98M59.32M62.66M74.17M83.18M87.80M94.75M111.77M130.14M142.73M139.83M151.11M
Operating Income (Quarter)
-26.09M-27.81M-30.89M-33.83M-43.05M-43.45M-47.56M-47.98M-52.99M-58.98M-62.66M-73.53M-82.78M-87.80M-94.75M-111.41M-129.11M-142.59M-133.67M-140.38M
EBIT (Quarter)
-26.09M-27.81M-30.89M-33.83M-43.05M-43.45M-47.56M-47.98M-52.99M-58.98M-62.66M-73.53M-82.78M-87.80M-94.75M-111.41M-129.11M-142.59M-133.67M-140.38M
Non-operating items
Non Operating Investment Income (Quarter)
-1.01M-1.00M-4.20M-0.47M
Interest & Investment Income (Quarter)
0.02M-0.02M0.08M0.19M-1.43M-1.39M-5.96M1.42M2.11M2.57M-1.81M7.32M-0.34M2.23M14.37M14.83M13.46M0.59M-0.21M12.66M
Other Non Operating Income (Quarter)
-0.04M-0.22M-0.20M-0.05M-0.12M-0.13M
Non Operating Income (Quarter)
-0.03M-0.04M0.01M0.21M-0.08M1.53M0.09M1.98M2.02M2.52M6.76M7.07M-0.01M10.97M14.15M14.63M13.47M12.49M11.03M12.53M
Net income details
EBT (Quarter)
26.09M27.85M-184.49M33.62M42.38M41.92M44.99M45.99M50.98M56.46M-362.77M66.46M74.06M-76.83M-80.59M96.77M115.64M-130.09M-122.64M-249.27M
Profit After Tax (Quarter)
-26.10M-27.85M-31.16M-34.63M-42.38M-43.32M-48.54M-45.99M-50.17M-57.46M156.27M-66.93M-74.39M-74.60M-1.07M1.04M-0.38M-130.09M-0.33M-127.84M
Income from Continuing Operations (Quarter)
26.09M27.85M-184.49M33.62M42.38M41.92M44.99M45.99M50.98M56.46M-362.77M66.46M74.06M-76.83M-80.59M96.77M115.64M-130.09M-122.64M-249.27M
Consolidated Net Income (Quarter)
26.09M27.85M-184.49M33.62M42.38M41.92M44.99M45.99M50.98M56.46M-362.77M66.46M74.06M-76.83M-80.59M96.77M115.64M-130.09M-122.64M-249.27M
Income towards Parent Company (Quarter)
26.09M27.85M-184.49M33.62M42.38M41.92M44.99M45.99M50.98M56.46M-362.77M66.46M74.06M-76.83M-80.59M96.77M115.64M-130.09M-122.64M-249.27M
Net Income towards Common Stockholders (Quarter)
26.09M27.85M-184.49M33.62M42.38M41.92M44.99M45.99M50.98M56.46M-362.77M66.46M74.06M-76.83M-80.59M96.77M115.64M-130.09M-122.64M-249.27M
Additional items
EPS (Basic) (Quarter)
0.700.73-4.800.700.810.780.870.850.940.99-6.250.920.94-0.96-1.001.041.23-1.38-1.30-2.39
EPS (Diluted) (Quarter)
0.700.73-4.800.700.810.780.870.850.940.99-6.250.920.94-0.96-1.001.041.23-1.38-1.30-2.39
Shares Outstanding (Quarter)
37.06M38.31M38.44M47.71M52.52M53.77M51.98M53.91M54.27M56.81M58.07M72.29M79.01M80.09M80.78M93.10M93.79M94.22M94.06M104.10M
Shares Outstanding (Diluted) (Quarter)
37.06M38.31M38.44M47.71M52.52M53.77M51.98M53.91M54.27M56.81M58.07M72.29M79.01M80.09M80.78M93.10M93.79M94.22M94.06M104.10M
EBITDA (Quarter)
-26.09M-27.81M-30.89M-33.83M-43.05M-43.45M-47.56M-47.98M-52.99M-58.98M-62.66M-73.53M-82.78M-87.80M-94.75M-111.41M-129.11M-142.59M-133.67M-140.38M
Interest Expenses (Quarter)
33.25M41.98M0.30M43.37M23.99M27.76M0.30M14.26M22.27M144.67M-0.20M341.74M288.96M356.63M-1.55M2.00M81.27M201.91M-3.31M121.56M